If you have been reading about clinical development and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-07-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Delayed stomach emptying creates especially favorable conditions for the shock lactic acidosis, because the digestive system may meanwhile still inhibit fatty acid release and oxidation, helping more muscles to run out of glycogen in those persons, who are otherwise still able to maintain its stores between meals. It has been experimentally demonstrated, that delayed gastric emptying prolongs the duration of the GLP-1 signal. Notably, a small quantity of dietary fructose does not produce this effect (the lactic acidosis), as it is captured by liver and may be fully expended for replenishing liver glycogen. Once all AMP has been recharged to ATP, and glycogen stores allowed to replenish, the cell transitions back to the unmodified original state. If carbohydrate-rich food is not consumed in this state, AMP elimination from the cell eventually completes, glycogen stores can be replenished again, and the cell transitions back to the original state but with reduced ATP pool and an up-regulated citric acid cycle. It may be especially important to have adequate dietary iodine in the glycogen-less state, so that stomach emptying is not excessively delayed, the up-regulation of the citric acid cycle in muscle cells in response to a load increment is not too slow, and the muscles can each time accept a bigger load increment relative to the perceived effort.
== Acquisition == HSBC UK announced on March 13, 2023, that it had agreed to acquire Silicon Valley Bank UK for £1, at no cost to taxpayers and with depositors fully protected. On March 26, 2023, the FDIC announced that First Citizens BancShares will acquire the commercial banking business of SVB. As part of the deal, First Citizens will buy around $119 billion in deposits and $72 billion of SVB's loans discounted by $16.5 billion, while around $90 billion of SVB's securities will continue to remain in receivership. The FDIC received about $500 million-worth of equity appreciation rights linked to First Citizens' shares. SVB's 17 branches reopened as a division of First Citizens Bank the next day, with all SVB depositors becoming depositors of First Citizens. SVB Private was initially going to be auctioned separately but First Citizens acquired the business along with SVB. First Citizens was the 30th-largest bank in the United States, in terms of assets, at the end of 2022. After the acquisition, it is set to enter the top 20. In April 2023, Centerview Partners began orchestrating an auction of SVB Securities. In June 2023, SVB Financial Group announced that it entered into an agreement to sell SVB Securities to a group led by Leerink.
Intraoperative stimulation has been employed a prognostic tool in people undergoing neurolysis surgery following nerve injury, where lower stimulation thresholds are associated with better postoperative motor recovery, whereas absent responses are associated with poor motor recovery, potentially warranting additional surgical interventions. Surgery can be done in case a nerve has become cut or otherwise divided, as well as when no recovery is achieved many months after injury. Recovery of a nerve after surgical repair depends mainly on the age of patients. Younger people fare better for prognosis due to the healing capacity of young tissues. Young children can recover almost normal nerve function. In contrast, a person over 60 years old with a cut nerve in the hand would expect to recover only protective sensory function, that is, the ability to distinguish hot/cold or sharp/dull; recovery of motor function would be likely incomplete. Many other factors also affect nerve recovery. An expanding area of nerve regeneration research deals with the development of scaffolding and bio-conduits. Scaffolding developed from bio-compatible material would be useful in nerve regeneration if they successfully exhibit essentially the same role as the endoneurial tubes, Schwann cells and epineurial fibroblasts do in guiding regrowing axons.
According to Historian of Art Benjamin Rowland, the portraits in Kizil show "that the Tocharians were European rather than Mongol in appearance, with light complexions, blue eyes, and blond or reddish hair, and the costumes of the knights and their ladies have haunting suggestions of the chivalric age of the West". The Chinese named Kuchean kings by adding the prefix "白", meaning "white", probably pointing to the fair complexion of the Kucheans. The Chinese Monk Xuanzang in 645 CE, noted that "they clothe themselves with ornamented garments of silk and embroidery". This cave also shows Central Asian traders encountering various dangers on their way, such as being lost in the dark, and being saved by the Dragon-King Mabi. Another is the story of the good merchant Sabu (萨缚), who, in order to show the way to a party of 500 merchants lost in the darkness, puts his own arms on fire to use them as torches, and successfully rescues them. The story appears in numerous paintings, in which the merchants are in Central Asian garb and accompanied by camels, and Sab has the attributes of a Bodhisattva. Cave 17 is contemporary with the earliest decorated Mogao Caves near Dunhuang (caves 268, 272 and 275), which were built and decorated by the Northern Liang between 419 and 439 CE, before the invasion of the Northern Wei. They have many stylistic characteristics in common.
Sources: en.wikipedia.org
== Variation in other animals == Stanniocalcin was also detected in mammals. In mammals there are two variant forms, STC1, which is fundamentally similar to fish stanniocalcin, and STC2, which is more different in structure and function. In invertebrates, freshwater leeches are found to contain the hormone. In leeches it is produced in the fat cells (adipocytes).
=== 2005–present: A new look === On 17 December 2005, the organisation obtained a new corporate identity. The previous NOS logo was in use for 36 years and featured the company's initials in lowercase, with round and obtuse angles. The O of the logo is painted red and represents "the hub of 360-degree reportage". The new logo was designed by graphic designers Lambie-Nairn, complete with new idents for its television programmes. The typeface was Gotham. Its news-gathering operations also changed, with the news departments for radio, television, and internet merging and reorganising into different sections (NOS, NOS News, NOS Sports, with NOS Events added in 2009). An announcement made by the Minister of Education in 2007 confirmed a further division of the NOS. The umbrella group Publieke Omroep, managed by the NOS was to be legally separated and renamed Nederlandse Publieke Omroep (Netherlands Public Broadcasting). The move was to ensure the NOS operated under the same conditions as its fellow broadcasting associations, as well as transferring membership of the European Broadcasting Union. In 2009, the NOS became fully independent and now has its own Board of Directors. Since 2012, the NOS has got a new style and layout and, for some programs, other titles. The biggest change is visible in the 8 o'clock NOS Journaal (traditionally the most viewed and therefore the most important news broadcast of the NOS), where they adopted a standing presentation.
canis is also unique from other Brucella species in that they demonstrate a distinctive phospholipid arrangement that differ greatly from other Gram-negative bacteria. Their envelope incorporates uncommon lipid species such as altered phosphatidylethanolamine and lipid A derivatives enriched with long-chain and branched fatty acids; features that reflect evolutionary adaptation to an intracellular lifecycle. Additionally, its phospholipid portion is mainly composed of cis-vaccenic cyclopropane with small amounts of lactobaccilic acid. This differs from other Brucella species, as they demonstrate the opposite composition, with lactobacillic acid making up the majority of the phospholipid fraction. Brucella is unusual in this composition because lactobacillic acid is typically within Gram-positive organisms but not common within Gram-negative organisms such as Brucella. These specific envelope features are discussed alongside the organisms hallmark intracellular cycle. After uptake, Brucella replicate within ER-derived Brucella containing vacuoles, a niche specific to replication and survival within B. canis.
==== Companion of the Order of the Bath (CB) ==== Military Division Royal Navy Major General Simon James Pack, . Surgeon Vice Admiral Anthony Leslie Revell, . Army Major General Jeremy Joseph Julian Phipps (472598), late The Queen's Own Hussars. Major General Michael Ian Eldon Scott, . (467628), late Scots Guards. Major General Michael Alan Willcocks (476673), late Royal Regiment of Artillery. Royal Air Force Air Vice-Marshal Geoffrey Wellesley Carleton. Air Vice Marshal Terence Brian Sherrington, . Civil Division Elizabeth Ann Chant, Chief Executive, Child Support Agency, Department of Social Security. George Michael Devereau, lately Chief Executive, Central Office of Information. David James Essery, Head of Group 1, Home Department, Scottish Office. David Gibson. For public service. Brian Richard Hawtin, lately Assistant Under Secretary (Home & Overseas), Ministry of Defence. David Alan Hogg, Deputy Treasury Solicitor, Treasury Solicitor's Department. James McQuaid, Chief Scientist, Health and Safety Executive, Department of the Environment. Arthur John Pryor, lately Head, Competition Policy Division, Department of Trade and Industry. Stephen Arthur Robson, Director, Finance Regulation and Industry Directorate, Her Majesty's Treasury. Terence Anthony Rochester, Chief Highway Engineer, the Highways Agency, Department of Transport. Professor Clive Harrod Smee, Chief Economic Adviser and Director of Operational Research, Department of Health. Christopher Camplin Wilcock, lately Head, Nuclear Power Privatisation Team, Department of Trade and Industry.
As such, it is far more suitable for men for whom long-term medication is being chosen. Mineralcortocoid receptor antagonists (MRA) as a class (including spironolactone, canerenone, eplerenone and finerenone) are cornerstones of heart failure with reduced ejection fraction (HFrEF EF≤40%) management, however, the comparative magnitude of effect on mortality between agents remains uncertain. Primarily, evidence explores spironolactone and eplerenone, with limited comparative data available for canerenone. Furthermore, there is limited evidence for benefit of finerenone in a HFrEF patient cohort, a newer agent recently licensed for the treatment of chronic kidney disease (CKD) in type 2 diabetes mellitus.
Sources: en.wikipedia.org
are calculated for a short time frame, and the matrices for longer periods of time are calculated by assuming mutations follow a Markov chain model. The base unit of time for the PAM matrices is the time required for 1 mutation to occur per 100 amino acids, sometimes called 'a PAM unit' or 'a PAM' of time. This is precisely the duration of mutation assumed by the PAM1 matrix. The constant
Cyclodextrins were called "cellulosine" when first described by A. Villiers in 1891. Soon after, F. Schardinger identified the three naturally occurring cyclodextrins: α, β, and γ, referred to as "Schardinger sugars". For 25 years, between 1911 and 1935, Hans Pringsheim in Germany was the leading researcher in this area, demonstrating that cyclodextrins formed stable aqueous complexes with many other chemicals. By the mid-1970s, each of the natural cyclodextrins had been structurally and chemically characterized and many more complexes had been studied. Since the 1970s, extensive work has been conducted by Szejtli and others exploring encapsulation by cyclodextrins and their derivatives for industrial and pharmacologic applications. Among the processes used for complexation, the kneading process seems to be one of the best.
== Working == A basic TDLAS setup consists of a tunable diode laser light source, transmitting (i.e. beam shaping) optics, optically accessible absorbing medium, receiving optics and detector/s. The emission wavelength of the tunable diode laser, viz. VCSEL, DFB, etc., is tuned over the characteristic absorption lines of a species in the gas in the path of the laser beam. This causes a reduction of the measured signal intensity due to absorption, which can be detected by a photodiode, and then used to determine the gas concentration and other properties as described later. Different diode lasers are used based on the application and the range over which tuning is to be performed. Typical examples are InGaAsP/InP (tunable over 900 nm to 1.6 μm), InGaAsP/InAsP (tunable over 1.6 μm to 2.2 μm), etc. These lasers can be tuned by either adjusting their temperature or by changing injection current density into the gain medium. While temperature changes allow tuning over 100 cm−1, it is limited by slow tuning rates (a few hertz), due to the thermal inertia of the system. On the other hand, adjusting the injection current can provide tuning at rates as high as ~10 GHz, but it is restricted to a smaller range (about 1 to 2 cm−1) over which the tuning can be performed. The typical laser linewidth is of the order of 10−3 cm−1 or smaller. Additional tuning, and linewidth narrowing, methods include the use of extracavity dispersive optics.
The U.S. Department of Health and Human Services agency responsible for ensuring the safety and effectiveness of all drugs, biologics, vaccines, and medical devices, including those used in the diagnosis, treatment, and prevention of HIV infection, AIDS, and AIDS-related opportunistic infections. The FDA also works with the blood banking industry to safeguard the nation's blood supply. Internet address: https://www.fda.gov/. (NLM) Frequentist methods
=== Livestock feed === One of the major uses of soybeans globally is as livestock feed, predominantly in the form of soybean meal. In the European Union, for example, though it does not make up most of the weight of livestock feed, soybean meal provides around 60% of the protein fed to livestock. In the United States, 70 percent of soybean production is used for animal feed, with poultry being the number one livestock sector of soybean consumption. The American Soybean Association estimates that over 90% of U.S. soybeans are used as animal feed and 97% of soybean meal feeds livestock and poultry. Spring grasses are rich in omega-3 fatty acids, whereas soy is predominantly omega-6. The soybean hulls, which mainly consist of the outer coats of the beans removed before oil extraction, can also be fed to livestock and whole soybean seeds after processing.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。